Reuters logo
6 months ago
BRIEF-Gilead COO says slowdown in patients starting hep C therapies to continue in 2017
January 9, 2017 / 7:50 PM / 6 months ago

BRIEF-Gilead COO says slowdown in patients starting hep C therapies to continue in 2017

1 Min Read

Jan 9 (Reuters) - Gilead Sciences Inc

* Gilead exec says slowdown in patients starting hepatitis c therapies to continue in 2017

* Gilead exec says hep c sales slowdown most apparent in Japan, southern Europe and United States - JP Morgan healthcare conference

* Gilead COO Kevin Young says not sure when hepatitis c sales decline will bottom out Further company coverage: (Reporting By Caroline Humer)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below